Clinical trial · no report yet · Phase 3
NCT07365995
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- NCT07365995 ↗
- Recruiting
- BioNTech SE
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- BNT324; Docetaxel; Prednisone/prednisolone
- Arms
- BNT324 · Experimental
- Docetaxel plus prednisone/ prednisolone · Active comparator
- Enrollment
- 736 (estimated)
- Primary outcomes
- rPFS assessed by BICR
- OS
- Sponsor
- BioNTech SE with BioNTech (Shanghai) Pharmaceuticals Co., Ltd., DualityBio Inc.
- Start
- Apr 22, 2026
- Primary completion
- Feb 2031 (estimated)
- Results posted
- No
- Registry record
- NCT07365995 · updated Oct 16, 2026